Results 81 to 90 of about 10,090 (144)

Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes. [PDF]

Viruses
Pickering RT, Asundi A, Olson A, Soden K, Lin NH.   +4 more
europepmc   +1 more source

Combined tenofovir, lamivudine, and dolutegravir treatment increases leptin and FABP4 expression in human subcutaneous adipose tissue. [PDF]

Einstein (Sao Paulo)
Zanardo LW, Izabel LDS, Hamada LM, Carvalho MB, Silva PAGOE, Joaquim HDG, Santoro S, Festuccia WT, Magdalon J.   +8 more
europepmc   +1 more source

Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States. [PDF]

Drugs Aging
Kong AM, Lucia J, Christoph MJ, Mordi U, Joseph D, Askin G, Yucuma D, Menezes NP, McMahon P, Lim T.   +9 more
europepmc   +1 more source

Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care. [PDF]

Infect Dis Ther
Li S, Mordi U, Christoph MJ, Guo H, Gilbertson DT, Cui T, Lim T, Prata Menezes N, Zachry W, Tien PC.   +9 more
europepmc   +1 more source

HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir. [PDF]

Commun Med (Lond)
Mchantaf G, Melard A, Da Silva K, Gardiennet E, Chaillon A, Lefebvre B, Ghosn J, Robineau O, Viard JP, Adoux L, Lemoine F, Barrail-Tran A, Orr S, Coulibaly F, Meyer L, Cheret A, Avettand-Fenoel V.   +16 more
europepmc   +1 more source

Factors Associated With Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda. [PDF]

J Acquir Immune Defic Syndr
Nutt CT, Muyindike WR, Nanfuka V, Komukama N, Barigye IT, Kansiime L, Tumusiime J, Omoding D, Aung TN, Stuckwisch A, Hedt-Gauthier B, Hoeppner SS, Marconi VC, Moosa MS, Gupta RK, Siedner MJ, McCluskey SM.   +16 more
europepmc   +1 more source

High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence. [PDF]

AIDS Res Ther
Girón-Callejas A, Lorenzana R, Pickles M, Inzaule S, Jordan MR, Diaz S, Vrinten C.   +6 more
europepmc   +1 more source

Distribution and efficacy of dolutegravir-based regimens in the main HIV outpatient care in Caracas, Venezuela. [PDF]

AIDS Res Ther
Alvarado-Bruzual MF, Mendoza-Merlo VA, Martinez-Torres JA, Guerra-Reyes LJ, Guevara RN, Carballo M, Redondo MC, Landaeta ME, Forero-Peña DA.   +8 more
europepmc   +1 more source

National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing. [PDF]

J Antimicrob Chemother
Martínez-Buitrago E, Zapata-Marín AF, Rubiano LC, Sañudo LM, Oñate JM, Lenis W, García-Góez JF, Álvarez JE, García-Morales C, Matías-Florentino M, Ávila-Ríos S.   +10 more
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source